Abstract
The development of compact MRI technology has increased the accessibility of this modality for cancer researchers interested in experimental therapeutics. In order to assess the utility of compact MR for use in this setting, several tumor models were evaluated using a variety of imaging sequences, including genetically engineered models of pancreatic cancer, bladder cancer, prostate cancer, glioma, and others. Dr. Olive will review the results of 3D tumor volume reconstructions to monitor response to therapy, as well as contrast imaging applications.
Cancer, Pancreatic Cancer, Therapeutic Response
Cancer, Pancreatic Cancer, Contrast Agents
ICON, VivoQuant
Kenneth P. Olive, Ph.D.
Assistant Professor of Medicine and Pathology & Cell Biology, Columbia University, New York, NY
